Evidence map›Paper›PMID 30792480›Full record

ReviewNature reviews. Nephrology2019

Pre-eclampsia: pathogenesis, novel diagnostics and therapies.

Elizabeth A Phipps, Ravi Thadhani, Thomas Benzing, S Ananth Karumanchi

Erratum issued Registry-linked trialOpen access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Nature reviews. Nephrology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04767438 (STUDY PROTOCOL FOR A PROSPECTIVE, MULTICENTRE, COHORT STUDY), which is not on this map. Cited by 561 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
561citing papers in PubMed, 11 pooled it
98.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04767438 unknown statusnot on this mapstarted 2021, after this paper: background citation

STUDY PROTOCOL FOR A PROSPECTIVE, MULTICENTRE, COHORT STUDY: Preeclampsia Sequential Screening Using Angiogenic Factors During First Trimester of Pregnancy (CRISP STUDY)

TypeobservationalSponsorInstituto de Investigación Sanitaria AragónRan2021 to 2022Enrolled6,560ConditionsPre-Eclampsia, Pregnancy ComplicationsArmsPregnant women
3 · Its place in the literature

Who cites it

561 citing papers in PubMed, 11 syntheses or guidelines pooled it, 1,149 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

501 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

Elizabeth A PhippsNephrology Division, Brigham and Women's Hospital, Boston, MA, USA.
Ravi ThadhaniNephrology Division, Massachusetts General Hospital, Boston, MA, USA.
Thomas BenzingDepartment II of Internal Medicine and Center for Molecular Medicine Cologne, University of Cologne, Cologne, Germany.
S Ananth KarumanchiDepartments of Medicine and Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA. SAnanth.Karumanchi@csmc.edu.ORCID http://orcid.org/0000-0002-2281-6831
Cedars-Sinai Medical Center · USBrigham and Women's Hospital · USUniversity of Cologne · DE

Funding

TRAINING PROGRAM IN ACADEMIC NEPHROLOGYT32DK007527 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT · 1986 to 2021
$8.8M
NIDDK NIH HHS T32 DK007527
6 · The paper itself

Abstract

Pre-eclampsia is a complication of pregnancy that is associated with substantial maternal and fetal morbidity and mortality. The disease presents with new-onset hypertension and often proteinuria in the mother, which can progress to multi-organ dysfunction, including hepatic, renal and cerebral disease, if the fetus and placenta are not delivered. Maternal endothelial dysfunction due to circulating factors of fetal origin from the placenta is a hallmark of pre-eclampsia. Risk factors for the disease include maternal comorbidities, such as chronic kidney disease, hypertension and obesity; a family history of pre-eclampsia, nulliparity or multiple pregnancies; and previous pre-eclampsia or intrauterine fetal growth restriction. In the past decade, the discovery and characterization of novel antiangiogenic pathways have been particularly impactful both in increasing understanding of the disease pathophysiology and in directing predictive and therapeutic efforts. In this Review, we discuss the pathogenic role of antiangiogenic proteins released by the placenta in the development of pre-eclampsia and review novel therapeutic strategies directed at restoring the angiogenic imbalance observed during pre-eclampsia. We also highlight other notable advances in the field, including the identification of long-term maternal and fetal risks conferred by pre-eclampsia.

Indexed as

Pre-EclampsiaAngiogenesis InhibitorsBiomarkersFemaleHumansPlacentaPregnancyRisk FactorsAngiogenesis InhibitorsBiomarkers

Identifiers

PMID30792480
PMCPMC6472952
OpenAlexW2916697167

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.